论文部分内容阅读
目的初步探讨生长激素释放激素受体(GHRHR)在肾上腺肿瘤组织中的表达及其在临床中的实际应用价值。方法应用免疫组织化学方法检测2001年1月-2009年10月间187例肾上腺肿瘤和20例正常肾上腺组织标本中GHRHR的表达。结果肾上腺皮质肿瘤与肾上腺髓质肿瘤、正常肾上腺组织比较,GHRHR表达明显增高(阳性率分别为99%、45%、55%),GHRHR在肾上腺皮质醇瘤和醛固酮瘤中表达的差异有统计学意义,在肾上腺皮质腺瘤、皮质腺癌、皮质增生中表达的差异有统计学意义。结论 GHRHR在人正常肾上腺及肾上腺肿瘤组织中的表达,为在垂体外组织及人类肿瘤组织存在GHRHR的表达提供了直接证据;GHRHR可能会用于肾上腺皮质肿瘤和髓质肿瘤的鉴别诊断,但GHRHR尚不能用于良性和恶性肾上腺皮质肿瘤的鉴别诊断。GHRHR在肾上腺皮质相关肿瘤的高表达,可能与肾上腺皮质肿瘤的发病机制有关。
Objective To investigate the expression of growth hormone releasing hormone receptor (GHRHR) in adrenal tumors and its clinical value. Methods Immunohistochemistry was used to detect the expression of GHRHR in 187 adrenal tumors and 20 normal adrenal glands from January 2001 to October 2009. Results The expression of GHRHR in adrenal cortex tumors was significantly higher than that in adrenal tumors and normal adrenal glands (positive rates were 99%, 45% and 55%, respectively). The difference of GHRHR expression between adrenocortical tumors and aldosterone tumors was statistically significant Significance, in adrenocortical adenoma, cortical adenocarcinoma, cortical hyperplasia in the expression of the difference was statistically significant. Conclusions The expression of GHRHR in human normal adrenal gland and adrenal tumor tissue provides direct evidence for the presence of GHRHR in the extra-pituitary tissues and human tumor tissues. GHRHR may be used for the differential diagnosis of adrenocortical and medullary tumors. However, GHRHR Not yet used for the differential diagnosis of benign and malignant adrenocortical tumors. The high expression of GHRHR in adrenocortical related tumors may be related to the pathogenesis of adrenocortical tumors.